Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 2508

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 9C
Chunk 2508
---
 committee’s charter. 

The compensation committee retains
sole authority to hire any compensation consultant, approve such consultant’s compensation, determine the nature and scope of its
services, evaluate its performance, and terminate its engagement.

The compensation committee reviews
our compensation policies and practices for all employees, including our named executive officers, as they relate to risk management practices
and risk-taking incentives to assess and determine that there are no risks arising from these policies and practices that are reasonably
likely to have a material adverse effect on us.

Nominating Committee

The primary purpose of our nominating
committee is to assist our Board of Directors in promoting the best interest of the Company and our stockholders through the implementation
of sound corporate governance principles and practices. Our nominating committee met one time during the fiscal year ended March 31, 2025.
The functions of our nominating committee include, among other things:

    ●
    identifying, reviewing and evaluating candidates to serve on our Board of Directors; 

    ●
    determining the minimum qualifications for service on our Board of Directors; 

    ●
    developing and recommending to our Board of Directors an annual self-evaluation process for our Board of Directors and overseeing the annual self-evaluation process; 

    ●
    developing, as appropriate, a set of corporate governance principles, and reviewing and recommending to our Board of Directors any changes to such principles; and 

    ●
    periodically reviewing and evaluating our nominating committee’s charter. 

Compliance Committee

The primary purpose of our compliance
committee is to assist our Board of Directors with oversight of healthcare compliance risk management arising from the FDA, Office of
Inspector General, the U.S. Department of Justice and other federal, state or foreign corporate compliance requirements related to medical
devices that specifically govern the AKS, FCA, FD&C Act, FCPA, Sunshine Act and similar state laws, HIPAA, the AdvaMed Code, and similar
applicable state and local regulations and (when applicable) equivalent global requirements. Our compliance committee met one time during
the fiscal year ended March 31, 2025.

89

Director Candidates

Our Board of Directors has a critical
role in guiding our strategic direction and overseeing the management of our business, and accordingly, we seek to attract and retain
highly qualified directors who have sufficient time to engage in the activities of our Board of Directors and to understand and enhance
their knowledge of our industry and business plans. In evaluating the suitability of individual candidates, our Board of